Drugs / C105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00529581 | Nov 2006 → Mar 2008 | cognitive disorder, multiple sclerosis | Cognition Pharmaceuticals, LLC | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00529581 ↗ |